Get started
Author

Carlota Arenillas

Observed names: Arenillas, Carlota, C A Carlota Arenillas, C. Arenillas
ORCID: 0000-0001-7921-9117
Observed ORCID: 0000-0001-7921-9117
OpenAlex ID: A5087612229
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer
2022 · Elena Elez, Javier Ros, et al. · Nature Medicine · 111
PDF
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia
2022 · Rodrigo A Toledo, Camilo Jimenez, et al. · Endocrine Reviews · 93
PDF
Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes
2025 · Carlota Arenillas, Lucía Celada, et al. · Cancer Discovery · 13
ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA
2023 · Ariana Huebner, James R. M. Black, et al. · Genome Medicine · 9
PDF
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
2025 · Elena Garralda, Charles Abbott, et al. · Clinical Cancer Research · 7
PDF
FDA fast-track approval of belzutifan is a milestone in rare cancer therapy
2025 · Carlota Arenillas, Rodrigo A. Toledo · Nature Reviews Endocrinology · 3
A multistakeholder call for belzutifan biomarker data in advanced pheochromocytoma and paraganglioma
2026 · Rodrigo A. Toledo, Carlota Arenillas, et al. · Trends in Endocrinology and Metabolism · 1
37O Plasma circulating tumor DNA (ctDNA) as a clinically relevant biomarker for disease monitoring and prognostication in metastatic pheochromocytoma and paraganglioma (mPPGL)
2025 · R.D.A. Toledo, C. Arenillas, et al. · ESMO Open · 1
PDF
Impact of circulating tumor DNA (ctDNA) detection on survival outcomes of patients (pts) treated with immune-checkpoint inhibitors (ICIs) in early clinical trials.
2021 · Vladimir Galvao, Ignacio Matos, et al. · Journal of Clinical Oncology · 1
Data from Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes
2025 · Carlota Arenillas, Lucía Celada, et al.
Supplementary Tables S1-S16 from Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes
2025 · Carlota Arenillas, Lucía Celada, et al.
Supplementary Figures S1-S23 from Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes
2025 · Carlota Arenillas, Lucía Celada, et al.
Supplementary Tables S1-S16 from Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes
2025 · Carlota Arenillas, Lucía Celada, et al.
Supplementary Figures S1-S23 from Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes
2025 · Carlota Arenillas, Lucía Celada, et al.
Pathophysiological features of neuroendocrine tumors in cyanotic congenital heart disease: a systematic review
2023 · B Miranda Barrio, R T Rodrigo Toledo, et al. · European Heart Journal
PDF
5. Características Clínicas Y Factores De Riesgo De Feocromocitomas Y Paragangliomas En Pacientes Con Cardiopatía Congénita Cianosante
2023 · Berta Miranda Barrio, Laura Dos Subirà, et al. · Revista Española de Cardiología
Additional file 2 of ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA
2023 · Huebner, Ariana, Black, James R. M., et al. · Figshare
Early changes in plasma cell-free DNA (cfDNA) as a predictive biomarker of immune checkpoint inhibitors (ICIs) efficacy
2019 · I. Matos Garcia, A. Moreno, et al. · Annals of Oncology
Works count: 20
Citation count: 239
H-index: 5
I10-index: 3
Year
Topic
Type